Lokivetmab (Cytopoint) 12-Month Durability: Pruritus Control and Owner Satisfaction

TL;DR

A 12-month prospective study found that 87% of dogs maintained pruritus visual analogue scale scores below their pre-treatment Day 0 baseline throughout lokivetmab therapy, with 93% of dog owners reporting satisfaction with treatment at month 6 and 86% at month 12.

What just dropped

• Gober et al. (2025, PMC11938560): Long-term use of lokivetmab (Cytopoint) in atopic dogs -- prospective 12-month study. At month 12, 87% of 75 dogs (64/75) maintained PVAS below baseline Day 0. Owner satisfaction was 93% (64/69) at month 6 and 86% (59/69) at month 12. (https://pmc.ncbi.nlm.nih.gov/articles/PMC11938560/)
• Michels et al. 2016 (PMID 27647513): Pivotal field study establishing single-dose efficacy with pruritus and CADESI-03 reductions at Day 28 following subcutaneous injection. (https://pubmed.ncbi.nlm.nih.gov/27647513/)

Context

Lokivetmab (Cytopoint) is a caninised anti-interleukin-31 (anti-IL-31) monoclonal antibody administered by subcutaneous injection. The pivotal field study demonstrated significant reductions in pruritus visual analogue scale (PVAS) scores and CADESI-03 lesion scores at Day 28 post-injection, establishing the clinical foundation for monthly re-injection intervals. IL-31 is a key mediator of itch in canine atopic dermatitis, signalling through IL-31 receptor complexes on sensory neurons and keratinocytes.

The 12-month prospective durability data from Gober et al. provide the longest prospective dataset for lokivetmab in atopic dogs. The 87% rate of dogs maintaining PVAS below Day 0 baseline over 12 months demonstrates sustained pruritus control without evidence of progressive loss of effect (tachyphylaxis). Owner satisfaction rates of 93% at month 6 and 86% at month 12 are high for a chronic disease management drug in this category. The modest decline from month 6 to month 12 satisfaction may reflect natural disease progression, seasonal variation, or other concurrent allergy management factors.

What this changes in Lokivetmab (Cytopoint) for Canine Atopic Dermatitis (https://www.thevoyage.ai/forvets/knowledge/lokivetmab-cytopoint-canine-atopic-dermatitis)

The 12-month durability data support lokivetmab as a long-term maintenance option rather than solely an acute flare intervention. For dogs achieving good PVAS control on monthly injections, there is a pharmacological and practical rationale to consider whether some patients might tolerate extended intervals (e.g., 6-8 weeks): IL-31 suppression may persist beyond 4 weeks in dogs with lower baseline IL-31 levels or milder disease, though no randomised data on extended intervals exist. Clinicians managing patients for cost reasons may wish to track individual PVAS trajectories across injection intervals to guide re-injection timing. In practice, the once-monthly label-approved interval remains appropriate as the default. All re-injection timing decisions should be based on clinical assessment and the product label.

Voyage Clinical Desk: https://www.thevoyage.ai/forvets/ask?context=lokivetmab-cytopoint-canine-atopic-dermatitis

References

1. Gober M et al. 2025. Long term use of lokivetmab (Cytopoint) in atopic dogs. Vet Dermatol 36(2). PMC11938560. https://pmc.ncbi.nlm.nih.gov/articles/PMC11938560/
2. Michels GM et al. 2016. An international randomised, double-blind, placebo-controlled clinical trial of the efficacy of a monoclonal anti-IL-31 antibody for the treatment of atopic dermatitis in client-owned dogs. Vet Dermatol 27(4):236-e57. PMID 27647513. https://pubmed.ncbi.nlm.nih.gov/27647513/

---

Related reads

• Lokivetmab (Cytopoint) for Canine Atopic Dermatitis: IL-31 Targeting and Clinical Evidence